Akagera Medicines

What Akagera Medicines does

Akagera Medicines is a clinical-stage biotechnology company developing liposomal nanotherapeutics and targeted mRNA vaccines for infectious diseases that disproportionately affect low- and middle-income countries, particularly tuberculosis, MRSA, NTM infections, Lassa Fever, HIV, RSV, and Influenza. Founded in 2018 in Kigali, Rwanda as a Delaware corporation, the company operates R&D laboratories in Boston and San Francisco and registered a 100%-owned subsidiary (Akagera Medicines Africa Ltd.) in Rwanda in 2022 for future manufacturing and clinical trials. The company is the only majority-African-owned biotech, with all 14 million Rwandan citizens as stakeholders through the Rwanda Social Security Board and four of five board members being Rwandan citizens.

The company's proprietary platform is built on lipid nanoparticle (LNP) and liposomal drug delivery technology, including patented ionizable lipids, ligand-targeting moieties for antigen-presenting cell delivery, and multivalent formulation capabilities supporting up to 7-8 mRNA molecules. Its clinical pipeline includes three therapeutic candidates (AKG-100 for pulmonary TB/MDR-TB/XDR-TB currently in Phase 1, AKG-120 for MRSA targeting osteomyelitis and infective endocarditis, and an NTM therapeutic) and five mRNA vaccine candidates for TB, Lassa Fever, HIV, RSV, and Influenza/Avian Flu. Lead TB drug candidates have demonstrated 16-67x greater potency than standard of care in preclinical studies with long-circulating pharmacokinetics (less than 10% release over 24 hours) and a strong preclinical toxicity profile. The technology is protected by 7 issued US patents and 79 global filings, with the USPTO characterizing it as novel with no prior art.

The company is pre-revenue and funded through a combination of equity rounds (A round at $1.00/share, B round at $7.62/share, C round at $25/share) and non-dilutive grants including €2 million from the European Investment Bank, approximately $14 million from the Bill and Melinda Gates Foundation for avian flu vaccine development, and additional support from CEPI and the European Union. Its go-to-market relies on strategic R&D partnerships with NIH/VRC, Gates Foundation, CEPI, and academic institutions (Harvard, Duke, Vanderbilt, Colorado State, Boston College, Oxford), with future revenue expected from product sales to governments, healthcare systems, and international health organizations (Global Fund, GAVI, WHO) following regulatory approval. The pricing model is oriented toward affordability and accessibility for LMIC markets rather than premium pricing.

Name

Akagera Medicines

Legal name

Akagera Medicines

Website

https://akageramedicines.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Akagera Medicines is a clinical-stage biotech developing liposomal nanotherapeutics and targeted mRNA vaccines for tuberculosis, MRSA, and neglected infectious diseases. The Rwanda-majority-owned company operates from Boston, San Francisco, and Kigali, with Phase 1 TB trials underway.

Ownership category

akta.pro rank

Product category

Infectious Disease Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industries

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA), Tuberculosis & Mycobacterial Diseases (HLAKAGAH)

Keywords

• Liposomal therapeutics
• MRNA vaccine platform
• Infectious disease vaccines
• Tuberculosis therapeutics
• Lipid nanoparticle delivery

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Akagera Medicines is a clinical-stage biotech company that does not yet generate revenue. The company is developing therapeutic products for tuberculosis (AKG-100, AKG-120), MRSA, and vaccine candidates for TB, Lassa Fever, HIV, RSV, and Influenza. Future revenue is expected from product sales to governments, healthcare systems, and international health organizations following regulatory approval.
2. Non-Dilutive Funding and Grants: The company receives significant non-dilutive financing from European Union, European Investment Bank (€2 million grant), CEPI, and Bill and Melinda Gates Foundation to support R&D activities. Approximately half of the company's $60M+ total funding is non-dilutive in nature.
3. Licensing and Partnership Agreements: Strategic partnerships with NIH/VRC, Gates Foundation, and CEPI provide funding and collaboration for specific pipeline programs. The company may pursue licensing agreements for its technology platform or individual product candidates in the future.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Akagera Medicines is a clinical-stage biopharmaceutical company that develops liposomal nanotherapeutics and mRNA-based vaccines for infectious diseases such as tuberculosis and MRSA. Its product pipeline comprises investigational drug candidates intended for use by public-health systems, governments, and global health partners.

Product overview

Akagera Medicines is a clinical-stage biotech company developing liposomal nanotherapeutics and mRNA vaccines for infectious diseases. The product portfolio includes three therapeutic candidates (AKG-100 for tuberculosis, AKG-120 for MRSA, and NTM therapeutics) delivered via their proprietary liposomal/LNP platform, plus five mRNA vaccine candidates targeting Tuberculosis, Lassa Fever, HIV, RSV, Influenza, and Avian Flu. The company utilizes a ligand-targeted lipid nanoparticle (LNP) delivery system for both therapeutics (encapsulating antibacterial drugs) and vaccines (delivering mRNA to dendritic cells). All products are designed with a focus on global health equity and accessibility for low and middle-income countries.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 16-67x more potent than standard of care for MDR and XDR tuberculosis
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core, major and minor.

• National Institute of Health (NIH) / Vaccine Research Council (VRC)coreStrategic or Co-development PartnerNIH/VRC is a key strategic partner for vaccine development. The partnership focuses on developing mRNA vaccines against tuberculosis, HIV, and Lassa Fever using Akagera's targeted LNP delivery system. Company policy limits indirect costs to 25% for R&D agreements.
• Vanderbilt Medical SchoolmajorStrategic or Co-development PartnerAcademic partner providing scientific collaboration and validation. MRSA therapeutic received favorable reviews from Duke and Vanderbilt Medical Schools. Key opinion leaders from these institutions support clinical development programs.
• Boston CollegemajorStrategic or Co-development PartnerAcademic partner in vaccine research with James Whitney conducting preclinical non-human primate modeling of vaccines at Boston College. Partnership supports HIV and emerging infectious disease vaccine development.
• Duke Medical SchoolmajorStrategic or Co-development PartnerAcademic partner providing scientific advisory and validation. MRSA therapeutic received favorable reviews from Duke and Vanderbilt. Science advisors from Duke participate in clinical trial planning and data review.
• Colorado State UniversitymajorStrategic or Co-development PartnerDr. Anne Lenaerts, Professor at Colorado State, leads Science Advisory Board. University is center for TB drug development with NIH/NIAID contract for mycobacterial infections. Partnership provides preclinical evaluation expertise.
• Institut Pasteur de DakarmajorStrategic or Co-development PartnerAkagera CSO Daryl Drummond presented at Institut Pasteur de Dakar in June 2025. Partnership supports African vaccine manufacturing and distribution strategy. Regional collaboration for West African disease threats including Lassa Fever.
• Oxford UniversitymajorStrategic or Co-development PartnerAcademic network partner providing scientific collaboration. Company remains networked into leading research universities including Oxford for TB vaccine and infectious disease research.
• Harvard Medical SchoolmajorStrategic or Co-development PartnerScience advisors from Harvard including Dr. Carole Mitnick participate in trial planning. Partnership with Harvard includes UGHE collaboration and clinical advisory board members. Multiple Harvard faculty on Science Advisory Board.
• BioNTechminorStrategic or Co-development PartnerFounders met BioNTech co-founder Dr. Özlem Türeci in Kigali at BioNTech manufacturing facility opening December 2023. Relationship noted in context of both companies focused on cancer and infectious disease treatments. No formal partnership announced.
• Rwanda Development BoardmajorStrategic or Co-development PartnerFrancis Gatare, Chief Executive of RDB and cabinet member, visited headquarters in March 2024. Ivan Kagame serves as director of Rwanda Development Board which integrates government agencies for investments. RDB instrumental in company's original launch.
• University of Global Health Equity (UGHE)majorStrategic or Co-development PartnerUGHE in Rwanda co-founded by Dr. Paul Farmer and Dr. Agnes Binagwaho. Company leadership engaged with UGHE including Dr. Daryl Drummond lecturing at University of Rwanda. Daniel Seifu, Dean of Research at UGHE, visited headquarters in November 2024.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Emerging players

• Talis Biomedical: Clinical-stage molecular diagnostics company with nanoparticle-based platform technology. While diagnostics-focused rather than therapeutics, comparable in using proprietary nanoparticle platform for infectious disease applications with small team and clinical-stage profile.
• TB Alliance: Non-profit product development partnership dedicated to developing and delivering improved tuberculosis treatments including pretomanid (approved for XDR-TB). Directly comparable to Akagera's AKG-100 program addressing MDR/XDR-TB, though TB Alliance is non-profit with different commercial model.

Regional players

• Institut Pasteur de Dakar: African vaccine manufacturer based in Senegal producing yellow fever and other vaccines for the African continent. Directly comparable in mission (African vaccine manufacturing sovereignty) and overlapping Lassa Fever vaccine development. Strategic partnership potential rather than direct competition.
• Biovac: South African biotechnology company manufacturing vaccines for the African market with established GMP manufacturing capability. Comparable African vaccine manufacturing focus, though more established commercially with broader product portfolio.

Broad incumbents

• Translate Bio (Sanofi): Translate Bio (acquired by Sanofi in 2021) developed mRNA therapeutics with proprietary lipid nanoparticle delivery platform. Now operating within Sanofi's broader infectious disease vaccine portfolio. Comparable LNP-mRNA platform technology though substantially larger scale.
• Moderna: Global leader in mRNA technology with infectious disease vaccine pipeline including HIV, RSV, and influenza programs. While broader in scope and substantially larger, Moderna competes directly with Akagera in mRNA vaccine development for LMIC-relevant indications and has partnered with GAVI/CEPI on similar global health initiatives.

Direct peers

• CureVac: mRNA therapeutics company developing vaccines for infectious diseases including rabies and COVID-19, with proprietary lipid nanoparticle delivery technology. Directly comparable on technology platform (mRNA + LNP) and target indications (infectious diseases, LMIC-relevant pathogens).
• Insmed: Commercial-stage biopharmaceutical company developing liposomal inhaled antibiotics including Arikayce for nontuberculous mycobacteria (NTM). Directly comparable to Akagera's AKG-120 (MRSA) and NTM programs given overlapping liposomal antibiotic delivery approach and infectious disease focus. Both target difficult-to-treat bacterial infections with liposomal formulations.
• Arcturus Therapeutics: Clinical-stage mRNA medicines company with proprietary lipid nanoparticle delivery platform (LUNAR) and pipeline in infectious disease vaccines (COVID-19, influenza) and rare diseases. Comparable to Akagera's combined mRNA + LNP platform approach for vaccines and therapeutics targeting global health indications.
• BioNTech: mRNA therapeutics pioneer with infectious disease vaccine pipeline including tuberculosis. BioNTech opened a manufacturing facility in Kigali, Rwanda in December 2023 in close geographic proximity to Akagera's planned operations. Both companies focus on mRNA vaccines for infectious diseases and operate in the African biomanufacturing space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@akageramedicines
• Xx.com/AkageraMedicine
• Facebookfacebook.com/100087267255938
• LinkedInlinkedin.com/company/akagera-medicines

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Akagera Medicines